LifeStance Health Group (LFST) Projected to Post Earnings on Wednesday

LifeStance Health Group (NASDAQ:LFST) is projected to post its Q1 2025 quarterly earnings results before the market opens on Wednesday, May 7th. Analysts expect the company to announce earnings of ($0.03) per share and revenue of $332.71 million for the quarter.

LifeStance Health Group Stock Up 4.3 %

NASDAQ LFST opened at $6.80 on Monday. LifeStance Health Group has a twelve month low of $4.64 and a twelve month high of $8.61. The stock has a market cap of $2.64 billion, a PE ratio of -26.15 and a beta of 1.30. The firm has a 50-day simple moving average of $6.88 and a 200 day simple moving average of $7.29. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.32 and a current ratio of 1.32.

Insider Activity

In related news, insider Lisa K. Miller sold 18,845 shares of the stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $6.90, for a total transaction of $130,030.50. Following the completion of the sale, the insider now owns 339,810 shares in the company, valued at $2,344,689. This trade represents a 5.25 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 6.60% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the company. William Blair reissued an “outperform” rating on shares of LifeStance Health Group in a report on Friday, February 28th. KeyCorp initiated coverage on shares of LifeStance Health Group in a report on Tuesday, April 8th. They issued an “overweight” rating and a $9.00 price target on the stock. Finally, Canaccord Genuity Group initiated coverage on shares of LifeStance Health Group in a report on Thursday, April 3rd. They set a “buy” rating and a $8.00 price objective for the company. One analyst has rated the stock with a sell rating, one has issued a hold rating, three have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $8.30.

LifeStance Health Group Company Profile

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.